WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H341003
CAS#: 5868-06-4 (bromide)
Description: Fentonium is an anticholinergic, antispasmodic and anti-ulcerogenic agent. It is quaternary analog of hyoscyamine, is a blocker of muscarinic activity and an allosteric blocker of α12βγε nicotinic receptors. It increases the spontaneous release of acetylcholine at the motor endplate without depolarizing the muscle or inhibiting cholinesterase activity. Fentonium inhibited transmitter release and depressed twitch without changing the responsiveness to noradrenaline or ATP. It is a K(+)-channel opener. Administration of fentonium bromide in rats receiving naloxone after chronic morphine treatment reduced the intensity of withdrawal signs such as increased defecation or micturition, salivation and wet-dog shakes, and elevated the nociceptive threshold values.
Hodoodo Cat#: H341003
Name: Fentonium bromide
CAS#: 5868-06-4 (bromide)
Chemical Formula: C31H34BrNO4
Exact Mass: 563.17
Molecular Weight: 564.520
Elemental Analysis: C, 65.96; H, 6.07; Br, 14.15; N, 2.48; O, 11.34
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 34786-74-8 (cation) 5868-06-4 (bromide)
Synonym: Fentonium bromide; FA 402; FA-402; FA402; Z 326; Z-326; Z326; Fa 402; Ketoscilium; Ketoscillium; Phenthonium; Phenthonium bromide ; Phentonium; Phentonium bromide; Ulcesium
IUPAC/Chemical Name: (1R,3r,5S,8R)-8-(2-([1,1'-biphenyl]-4-yl)-2-oxoethyl)-3-(((S)-3-hydroxy-2-phenylpropanoyl)oxy)-8-methyl-8-azabicyclo[3.2.1]octan-8-ium bromide
InChi Key: MPLNGQBULSHWQW-QRAMOEPWSA-M
InChi Code: InChI=1S/C31H34NO4.BrH/c1-32(20-30(34)25-14-12-23(13-15-25)22-8-4-2-5-9-22)26-16-17-27(32)19-28(18-26)36-31(35)29(21-33)24-10-6-3-7-11-24;/h2-15,26-29,33H,16-21H2,1H3;1H/q+1;/p-1/t26-,27+,28+,29-,32-;/m1./s1
SMILES Code: O=C(O[C@H]1C[C@@]([N@@+]2(C)CC(C3=CC=C(C4=CC=CC=C4)C=C3)=O)([H])CC[C@@]2([H])C1)[C@@H](C5=CC=CC=C5)CO.[Br-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 564.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Pinelli A, Trivulzio S, Tomasoni L. Effects of administration of phentonium bromide on opioid withdrawal syndrome in rats. J Pharm Pharmacol. 1997 Dec;49(12):1222-8. PubMed PMID: 9466347.
2: Milani R, Merlo E, Scalambrino S, Viganò R. A double-blind trial of fentonium bromide in the treatment of incontinent unstable bladder. Int J Clin Pharmacol Ther Toxicol. 1986 Aug;24(8):421-4. PubMed PMID: 3531034.
3: Rodrigo Sáez L, Alonso González JL, Cornago Sánchez A, Pérez Alvarez R, Sánchez Lombraña JL, Faedo Presa I. [Clinico-endoscopic study of the comparative therapeutic effectiveness of cimetidine alone or combined with fentonium bromide in gastric and duodenal ulcer]. Rev Esp Enferm Apar Dig. 1981 Jan;59(1):69-78. Spanish. PubMed PMID: 7209100.
4: Ricciardi S, Cerqua R. Controlled double-blind trial on the clinical effects of the chenodeoxycholic acid-fentonium bromide combination in the symptomatic treatment of biliary spastic-dyskinetic conditions. Arzneimittelforschung. 1977;27(6):1226-30. PubMed PMID: 332188.
5: Wilmana PF, Istiantoro J, Sinto A, Darmansjah I. Tolerability of fentonium bromide in Indonesian volunteers. Curr Med Res Opin. 1977;5(3):284-8. PubMed PMID: 162668.
6: Porsio A, Borgia M. Double-blind controlled trial of the new preparation FZ. 560 in the symptomatic treatment of digestive disorders. Int J Clin Pharmacol Biopharm. 1976 Jul;14(1):40-3. PubMed PMID: 61952.